Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alvocidib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 known ✓ | P24941 | 14/20 | 1.00 |
| ▸ | CDK4 known ✓ | P11802 | 12/20 | 1.00 |
| ▸ | CDK1 known ✓ | P06493 | 11/20 | 1.00 |
| ▸ | CDK9 known ✓ | P50750 | 10/20 | 1.00 |
| ▸ | CDK7 known ✓ | P50613 | 3/20 | 1.00 |
| ▸ | CDK6 known ✓ | Q00534 | 2/20 | 1.00 |
| ▸ | CCND1 | P24385 | 11/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 9/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 9/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 8/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 6/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 6/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 6/20 | 1.00 |
| ▸ | GSK3A | P49840 | 4/20 | 1.00 |
| ▸ | CCNE2 | O96020 | 4/20 | 1.00 |
| ▸ | GSK3B | P49841 | 3/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 3/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alvocidib SCHEMBL5868074 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL29351027 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL29577824 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL12445809 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL3652 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL8214028 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL3651 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL16927354 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Flavopyridol SCHEMBL22580715 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL28199338 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4412621-A2 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT Bio Corp. (US) | 2024-08-14 | — | — | EP | claimed |
| WO-2023056202-A2 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT BIO CORP. (US) | 2023-04-06 | — | — | WO | claimed |
| WO-2025235261-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING 2,4,5-SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CERTAIN CYCLIN-DEPENDENT KINASE VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| WO-2025235298-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING THIAZOLYL DERIVATIVES FOR DEGRADING CERTAIN CYCLIN-DEPENDENT KINASE VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250290076-A1 | EPICARDIAL CELL REGENERATION PROMOTER AND METHOD FOR PROMOTING EPICARDIAL CELL REGENERATION | KYOTO UNIVERSITY (JP) | 2025-09-18 | — | — | US | disclosed |
| EP-4615833-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING 2,5-SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | Nikang Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2025137391-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 4 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025137393-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASES 2, 4, AND 6 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025137385-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-D]P¥RIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 AND CYCLIN- DEPENDENT KINASE 4 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-4572804-A2 | INHALABLE COMPOSITIONS OF CDK9 INHIBITORS | The Regents of the University of California (US) | 2025-06-25 | — | — | EP | disclosed |
| WO-2025124415-A1 | TETRACYCLIC DERIVATIVES AS K-Ras G12D INHIBITORS | NIKANG THERAPEUTICS INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| CN-114621969-A | Targeted cytotoxic cells with chimeric receptors for adoptive immunotherapy | 诺华股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| EP-3994132-A1 | TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITORS AND USES THEREOF | Sumitomo Dainippon Pharma Oncology, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| US-11279694-B2 | Alvocidib prodrugs and their use as protein kinase inhibitors | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| WO-2022043558-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022043556-A1 | STABLE RADIOPHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022043557-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2022-03-03 | — | — | WO | disclosed |
| CN-114107424-A | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof | 诺华股份有限公司 | 2022-03-01 | — | — | CN | disclosed |
| WO-2022040586-A2 | COMPOSITIONS AND METHODS FOR IN VIVO GENERATION OF CAR EXPRESSING CELLS | NOVARTIS AG (CH) | 2022-02-24 | — | — | WO | disclosed |
| WO-2022033492-A1 | QUINOLINE COMPOUNDS AND COMPOSITIONS FOR INHIBITING EZH2 | NOVARTIS AG (CH) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11279694-B2 | Alvocidib prodrugs and their use as protein kinase inhibitors | CDK1, CDK2, CDK3 | CDK2 2/4885CDK4 4/4885CDK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.